.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA28_Belatacept.Belatacept .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA28_Belatacept.Belatacept| name: | Belatacept |
| ATC code: | L04AA28 | route: | intravenous |
| n-compartments | 2 |
Belatacept is a selective T-cell costimulation blocker used in organ transplantation to prevent organ rejection, specifically in adult patients receiving a kidney transplant. It is an immunosuppressive agent and is approved for clinical use.
Population pharmacokinetics in adult renal transplant recipients. Evaluation included both male and female patients, ages ranging from 18 to 69 years.
Moudgil, A, et al., & Ettenger, RB (2019). Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 19(4) 1218–1223. DOI:10.1111/ajt.15236 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30582294